At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Vonoprazandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents With Symptomatic Gastroesophageal Reflux Disease
In Brief
A Phase 1 clinical trial evaluating Vonoprazan for Gastroesophageal Reflux. Completed, enrolled 24 participants across 10 sites.
Detailed Summary
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionMay 2023
Study CompletionJun 2023
TodayJul 2026
First PostedApr 25, 2022
Enrollment StartMay 9, 2022
Primary CompletionMay 30, 2023
Study CompletionJun 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.2 years ago
Interventions
Vonoprazandrug
Oral Tablet